At this free online seminar, attendees will learn how sponsors in the field of neuroscience are rethinking patient identification, endpoint selection, and treatment response assessment in complex central nervous system (CNS) diseases. The keynote speakers will discuss how these factors affect the design and execution of clinical trials by incorporating cases from fields such as neurodegenerative diseases, psychiatry, and psychedelic medicine. Participants will also explore the scientific, operational, and regulatory trends that are expected to shape neuroscience development over the next five years.
Toronto, November 9, 2026 / PRNewswire / -- Clinical development in neuroscience is constantly evolving in the fields of Alzheimer's disease, Parkinson's disease, psychiatry, and other complex CNS diseases. Disease heterogeneity, trial accessibility, endpoint selection, and variability in treatment responses are challenging traditional methods regarding how sponsors identify patients, measure treatment effectiveness, and make development decisions.
Cases from emerging fields such as neurodegenerative diseases, psychiatry, and the medical use of psychedelic drugs will demonstrate how patient populations, endpoints, and methods of measuring treatment responses influence the design and conduct of trials. The discussion will also look ahead to the scientific, operational, and regulatory trends that may shape the development of neuroscience over the next five years.
Register for this webinar to learn how the evolving methods of clinical development in neuroscience can provide insights for patient identification, endpoint selection, and future clinical trial strategies.
Experts participating in the live seminar come from Syneos Health, including Jason Tibbs (moderator), the global treatment leader in neuroscience and ophthalmology; Alexandria Wise, the head of research and development and scientific strategy; and Zia Choudhry, also the head of research and development and scientific strategy. The seminar will be held on Tuesday, December 1, 2026, at 11 a.m. (Eastern Time of the United States, 5 p.m. Central European Time).
For more information or to register for the event, please visit “Neuroscience Development : Are We Measuring What Matters?”.
About Xtalks
Xtalks — The Life Sciences Community™ provides trusted knowledge and collaborative insights for professionals in the fields of pharmaceuticals, biotechnology, medical technology, healthcare, and research, driving the industry forward. Xtalks Operated by Honeycomb Worldwide Inc, it offers news, feature articles, webinars, podcasts, videos, expert interviews, and selected job opportunities, aiming to support informed decision-making in this rapidly changing industry.
Every year, thousands of professionals rely on Xtalks to obtain timely information, insights from their peers, and leadership in industry thought. Join our life sciences community to stay informed about the latest developments, maintain connections, and get ready for the next steps.
For more information about Xtalks, please visit www.xtalks.com.
For information on how to collaborate with Xtalks to host a webinar, please visit https :// xtalks.com / partner-with-us /.
Contact Information: Soumya Shashikumar Phone: +1 (416) 977-6555 x371 Email: [ email protected ]
